Inhibition of the alloantibody response by CD95 ligand

Nature Medicine

Volumn 3, Issue 8, 1997, Pages 843-848

  Arai, Hiroshi ^a   Chan, Sherri Y ^b   Bishop, D Keith ^b   Nabel, Gary J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Section of Orthopaedic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; FAS ANTIGEN;

ALLOIMMUNITY; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA TRANSFECTION; HELPER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODY FORMATION; FAS LIGAND PROTEIN; GENE TRANSFER TECHNIQUES; ISOANTIBODIES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0030857077     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0897-843     Document Type: Article

References (32)

1. Matzinger, P. & Bevan, M.J. Why do so many lymphocytes respond to major histocompatibility antigens? Cell. Immunol. 29, 1-5 (1977).
2. Sayegh, M.H., Watschinger, B. & Carpenter, C.B. Mechanisms of T cell recognition of alloantigen: The role of peptides. Transplantation 57, 1295-1302 (1994).
3. + T-cell dependent antibody-mediated graft rejection. Immunol. Today 13, 434-438 (1992).
4. Bishop, D.K., DeBruyne, L.A., Chan, S., Xu, S. & Eichwald, E.J. Dissociation of mouse cardiac transplant rejection and donor alloantigen-specific T cell responsiveness. Transplant. Immunol. 3, 222-228 (1995).
5. Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243 (1991).
6. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
7. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995).
8. Lynch, D.H., Ramsdell, F. & Alderson, M.R. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16, 569-574 (1995).
9. Dhein, J., Walczak, H., Baumler, C., Debatin, K. & Krammer, P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-441 (1995).
10. h2 cytokine production and alternate mechanisms of allograft rejection, Transplantation 59, 1155-1161 (1995).
11. Brunner, T. et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444 (1995).
12. Ju, S. et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444-448 (1995).
13. Zheng, L. et al. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature 377, 348-351 (1995).
14. Kupfer, A. & Singer, S. Cell biology of cytotoxic and helper T cell functions. Annu. Rev. Immunol. 7, 309(1989).
15. Harriman, W., Volk, H., Defranoux, N. & Wabl, M. Immunoglobulin class switch recombination. Annu. Rev. Immunol. 11, 361-384 (1993).
16. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177, 195(1993).
17. Garrone, P. et al. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 182, 1265-1273 (1995).
18. Schattner, E. et al. CD40 ligation induces APO-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J. Exp. Med. 182, 1557-1565 (1995).
19. Cleary, A.M., Fortune, S.M., Yellin, M.J., Chess, L. & Lederman, S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J. Immunol. 155, 3329-3337 (1995).
20. Daniel, P.T. & Krammer, P.H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152, 5624-5632 (1994).
21. Rothstein, T.L. et al. Protection again Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 374, 163-165 (1995).
22. Rathmell, J.C., Townsend, S.E., Xu, J.C, Flavell, R.A. & Goodnow, C.C. Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87, 319-329 (1996).
23. Bishop, D.K. et al. Helper T lymphocyte unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Transplantation 58, 576-584 (1994).
24. Griffith, T., Brunner, T., Fletcher, S., Green, D. & Ferguson, T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
25. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
26. Lau, H.T., Yu, M., Fontana, A. & Stoeckert, C.J., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112 (1996).
27. Yagita, H., Seino, K., Kayagaki, N. & Okumura, K. CD95 ligand in graft rejection. Nature 379, 682-683 (1996).
28. Plautz, G.E. et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 90, 4645-4649 (1993).
29. Ellison, J.W., Berson, B.J. & Hood, L.E. The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic. Acids. Res. 10, 4071-4079 (1982).
30. Orosz, C.G., Horstemeyer, B., Zinn, N.E. & Bishop, D.K. Development and evaluation of an LDA technique that can discriminate in vivo alloactivated CTL from their naive CTL precursors. Transplantation 47, 189-194 (1989).
31. Bishop, D.K. & Orosz, C. Limiting dilution analysis for alloreactive TCGF secretory T cells. Transplantation 47, 671-677 (1989).
32. Schroder, J.M., Mrowietz, U., Morita, E. & Christophers, E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J. Immunol. 139, 3474-3483 (1987).